Berbel L M Ykema1, Emilie C H Breekveldt1, Beatriz Carvalho2, Tom van Wezel2,3, Gerrit A Meijer2, Martijn Kerst4, Michael Schaapveld5, Flora E van Leeuwen5, Petur Snaebjornsson2, Monique E van Leerdam6,7. 1. Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. 2. Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands. 3. Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands. 4. Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. 5. Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands. 6. Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. m.v.leerdam@nki.nl. 7. Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands. m.v.leerdam@nki.nl.
Abstract
BACKGROUND: Non-seminoma testicular cancer survivors (TCS) have an increased risk of developing colorectal cancer (CRC) when they have been treated with platinum-based chemotherapy. Previously we demonstrated that among Hodgkin lymphoma survivors (HLS) there is enrichment of rare mismatch repair (MMR) deficient (MMRd) CRCs with somatic hits in MMR genes. We speculate that this phenomenon could also occur among other cancer survivors. We therefore aim to determine the MMR status and its underlying mechanism in CRC among TCS (TCS-CRC). METHODS: Thirty TCS-CRC, identified through the Dutch pathology registry, were analysed for MMR proteins by immunohistochemistry. Next-generation sequencing was performed in MMRd CRCs without MLH1 promoter hypermethylation (n = 4). Data were compared with a male cohort with primary CRC (P-CRC, n = 629). RESULTS: MMRd was found in 17% of TCS-CRCs vs. 9% in P-CRC (p = 0.13). MMRd was more often caused by somatic double or single hit in MMR genes by mutation or loss of heterozygosity in TCS-CRCs (3/30 (10%) vs. 11/629 (2%) in P-CRCs (p < 0.01)). CONCLUSIONS: MMRd CRCs with somatic double or single hit are more frequent in this small cohort of TCS compared with P-CRC. Exposure to anticancer treatments appears to be associated with the development of these rare MMRd CRC among cancer survivors.
BACKGROUND: Non-seminoma testicular cancer survivors (TCS) have an increased risk of developing colorectal cancer (CRC) when they have been treated with platinum-based chemotherapy. Previously we demonstrated that among Hodgkin lymphoma survivors (HLS) there is enrichment of rare mismatch repair (MMR) deficient (MMRd) CRCs with somatic hits in MMR genes. We speculate that this phenomenon could also occur among other cancer survivors. We therefore aim to determine the MMR status and its underlying mechanism in CRC among TCS (TCS-CRC). METHODS: Thirty TCS-CRC, identified through the Dutch pathology registry, were analysed for MMR proteins by immunohistochemistry. Next-generation sequencing was performed in MMRd CRCs without MLH1 promoter hypermethylation (n = 4). Data were compared with a male cohort with primary CRC (P-CRC, n = 629). RESULTS: MMRd was found in 17% of TCS-CRCs vs. 9% in P-CRC (p = 0.13). MMRd was more often caused by somatic double or single hit in MMR genes by mutation or loss of heterozygosity in TCS-CRCs (3/30 (10%) vs. 11/629 (2%) in P-CRCs (p < 0.01)). CONCLUSIONS: MMRd CRCs with somatic double or single hit are more frequent in this small cohort of TCS compared with P-CRC. Exposure to anticancer treatments appears to be associated with the development of these rare MMRd CRC among cancer survivors.
Authors: Tara O Henderson; Kevin C Oeffinger; John Whitton; Wendy Leisenring; Joseph Neglia; Anna Meadows; Catherine Crotty; David T Rubin; Lisa Diller; Peter Inskip; Susan A Smith; Marilyn Stovall; Louis S Constine; Sue Hammond; Greg T Armstrong; Leslie L Robison; Paul C Nathan Journal: Ann Intern Med Date: 2012-06-05 Impact factor: 25.391
Authors: L B Travis; R E Curtis; H Storm; P Hall; E Holowaty; F E Van Leeuwen; B A Kohler; E Pukkala; C F Lynch; M Andersson; K Bergfeldt; E A Clarke; T Wiklund; G Stoter; M Gospodarowicz; J Sturgeon; J F Fraumeni; J D Boice Journal: J Natl Cancer Inst Date: 1997-10-01 Impact factor: 13.506
Authors: Lois B Travis; Sophie D Fosså; Sara J Schonfeld; Mary L McMaster; Charles F Lynch; Hans Storm; Per Hall; Eric Holowaty; Aage Andersen; Eero Pukkala; Michael Andersson; Magnus Kaijser; Mary Gospodarowicz; Timo Joensuu; Randi J Cohen; John D Boice; Graça M Dores; Ethel S Gilbert Journal: J Natl Cancer Inst Date: 2005-09-21 Impact factor: 13.506
Authors: Harmke J Groot; Sjoukje Lubberts; Ronald de Wit; Johannes A Witjes; Jan Martijn Kerst; Igle J de Jong; Gerard Groenewegen; Alfons J M van den Eertwegh; Philip M Poortmans; Heinz-Josef Klümpen; Hetty A van den Berg; Tineke J Smilde; Ben G L Vanneste; Maureen J Aarts; Luca Incrocci; Alfons C M van den Bergh; Katarzyna Jóźwiak; Alexandra W van den Belt-Dusebout; Simon Horenblas; Jourik A Gietema; Flora E van Leeuwen; Michael Schaapveld Journal: J Clin Oncol Date: 2018-07-10 Impact factor: 44.544
Authors: Lorenzo Richiardi; Ghislaine Scélo; Paolo Boffetta; Kari Hemminki; Eero Pukkala; Jorgen H Olsen; Elisabete Weiderpass; Elizabeth Tracey; David H Brewster; Mary L McBride; Erich V Kliewer; Jon M Tonita; Vera Pompe-Kirn; Chia Kee-Seng; Jon G Jonasson; Carmen Martos; Paul Brennan Journal: Int J Cancer Date: 2007-02-01 Impact factor: 7.396
Authors: F E van Leeuwen; A M Stiggelbout; A W van den Belt-Dusebout; R Noyon; M R Eliel; E H van Kerkhoff; J F Delemarre; R Somers Journal: J Clin Oncol Date: 1993-03 Impact factor: 44.544
Authors: Alexandra W van den Belt-Dusebout; Ronald de Wit; Jourik A Gietema; Simon Horenblas; Marieke W J Louwman; Jacques G Ribot; Harald J Hoekstra; Gabey M Ouwens; Berthe M P Aleman; Flora E van Leeuwen Journal: J Clin Oncol Date: 2007-10-01 Impact factor: 44.544
Authors: A Horwich; S D Fossa; R Huddart; D P Dearnaley; S Stenning; M Aresu; J M Bliss; E Hall Journal: Br J Cancer Date: 2013-11-21 Impact factor: 7.640